Product name

EBVac- vaccine for prevention of Epstein-Barr virus infections from University Hospital Aachen

Summary

Recombinant Epstein-Barr Virus has lost oncogenic potential of wild type EBV

Organization name

Provendis GmbH

Profile

Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV) which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine.

The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of viral latency. Mutant virus infected B-lymphocytes died after the productive phase.

Advantages

• first save live vaccine for EBV
• live virus - overall immune response, sterile immunity
• no competing vaccines or cures known or on the market
• standardized recombinant production
• further scientific collaboration offered
• IP-protection

Contact

Dr. Juergen Walkenhorst

Tel: +49 208 94 105 25

jw(at)provendis.info

About PROvendis GmbH

PROvendis offers companies certified and patented innovations from 24 North Rhine-Westphalian universities. The core function of the enterprise is to market patentable and commercially exploitable inventions. PROvendis GmbH was founded in 2001 as a wholly owned subsidiary of Zenit GmbH, a management consultancy firm in cooperation with the state of North Rhine-Westphalia. Since January of 2002, PROvendis has been the service provider for the universities of the state of North Rhine-Westphalia. Within the scope of the BMBF commercialization campaign, the Federal Ministry for Education and Research (BMBF) supports the activities of PROvendis.

Description File

 313EBVac.pdf

URL

http://www.lifesciencepatente-nrw.de

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney